From: Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer
BT- 549
SUM 159
HCC 1187
Gemcitabine
13.5 nM
5.27 nM
17.1 nM
UCN-01
160.8 nM
116.4 nM
230.5 nM
AZD 7762
275.2 nM
509.1 nM
307.7 nM